Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Experimental cell injection aims to heal damaged kidneys

NCT ID NCT07275788

Summary

This early-stage study is testing the safety of an experimental treatment called REGEND003, which contains human kidney repair cells. Researchers want to see if injecting these cells directly into the kidneys is safe and tolerable for people with type 2 diabetes and chronic kidney disease. The study will enroll 15 participants to monitor for side effects and gather initial information on kidney function and quality of life.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES MELLITUS (T2DM) AND CHRONIC KIDNEY DISEASE (CKD) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Shanghai Tongji Hospital

    RECRUITING

    Shanghai, 200000, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.